Entrepreneurship requires skill, talent, and faith in backing yourself. Behind every success story lays a concept, an idea often created by an individual.
Step forward, Dr. Eric Leire, the CEO of GenFlow Biosciences. The company that has big ambitions to make your final years your healthiest. Eric has an impressive background in biotechnology, having held posts at Pfizer, Schering Plough, and Pharmacia. His success has also translated into academic research, where he has held a research position at Harvard University. He is also the inventor of several patents and serves on the board of several biotechnology companies, such as Pherecydes (ALPHE.PA), Immunethep, Inhatarget, and BSIM.
One of the more recent biomedical breakthroughs could be that of gene delivery. “We recently developed improved, more efficient tools to deliver genes (such as SIRT6 or kat7, which could assist in postponing the aging process. In addition, we can now supply genes into cells in an ethical, safe, and cost-effective manner without the integration of this gene into our chromosomes. We believe that combining these recent advances in gene delivery with better identification of the biological drivers of the aging process may unlock substantial benefits for Humans.”
GenFlow could be seen as a substantial risk-reward business with a considerable potential upside. Eric is working alongside renowned Venture Capitalist Ron Bauer to help fund and grow the business. Here, Eric discusses why he believes in the future success of anti-aging technology.
Eric discusses it could be an iceberg moment for this domain of science. “In his book in 2000, Malcolm Gladwell explains that small actions at the correct time can create a “tipping point”. This can be seen as a magic moment when an idea could spread like wildfire.” Eric considers that moment could be now for GenFlow and its contemporaries.
Eric discusses the renowned, Targeting Ageing with Metformin trial, which Israeli superstar Dr. Nir Barzilai has led. The test is a series of six-year clinical trials at 14 leading research centers across the USA engaging more than 3,000 subjects aged 65-79 and has already been accepted by the FDA. With TAME, for the first time, the FDA recognizes aging as an indication. This marks a paradigm shift, from treating each age-related disease separately to managing aging as a risk factor for these diseases.
Consequently, more and more people and Governments believe that life extension and even age-reversal will become possible in a few decades. Targeting aging through therapeutic interventions realistically holds the promise of extending years of health and drastically saving healthcare costs. Genflow Biosciences intends to be one of the triggers of the longevity tipping point and to participate in this upcoming longevity revolution.